PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiovascular diseases. Our lead product candidate is bentracimab (PB2452), a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB6440, a highly selective aldosterone synthase inhibitor in development for treatment resistant hypertension and potentially other cardio-renal indications.
May 19, 2022 11:10 AM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.
We use essential cookies to make our site work. These enable core functionality such as security and accessibility. Essential cookies are on by default. You can disable these by changing your browser settings, but this may affect how the website functions.
Google Analytics Cookies
We would like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. These cookies collect information in a way that does not directly identify anyone.